Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Phase 2 Completed 33 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD in Japanese population.

Timeline

Start: 2008-09
Primary completion: 2009-07
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Solanezumab	Protein / enzyme biologic	400 mg	Intravenous

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Summary

Timeline

Drugs

Indications